Rouan Sarah Kathryn
SEC insider (Form 3/4/5 filer). CIK 0001761366. Director at Viking Therapeutics, Inc. (VKTX). 5 reported Form 4/5 transactions since Sep 2024; latest on Jan 2, 2026. Located in SAN DIEGO, CA.
Companies Rouan Sarah Kathryn has filed insider reports for
- Viking Therapeutics, Inc. (VKTX): Director
Rouan Sarah Kathryn
CIK: 0001761366
Transaction Breakdown
Open Market Buys (P)1 (20.0%)
High conviction signal
Open Market Sales (S)1 (20.0%)
Position reduction
Option Exercises (M)1 (20.0%)
Derivative conversions
Awards (A)2 (40.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
VKTX
Viking Therapeutics, Inc.
Director
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jan 2, 2026VKTX
Viking Therapeutics, Inc.
AwardDirect3.2K shares- - Mar 31, 2025VKTX
Viking Therapeutics, Inc.
PurchaseDirect1.2K shares at avg. $24.15$30K - Jan 2, 2025VKTX
Viking Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
18.8K shares- - Oct 25, 2024VKTX
Viking Therapeutics, Inc.
ExerciseDirect11K shares at avg. $4.88$54K - Oct 25, 2024VKTX
Viking Therapeutics, Inc.
SaleDirect11K shares at avg. $80.89$890K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jan 2, 2026 | VKTX Viking Therapeutics, Inc. | Award | 3,150 | - | $0 | Direct |
| Mar 31, 2025 | VKTX Viking Therapeutics, Inc. | Purchase | 1,240 | $24.15 | $29,943 | Direct |
| Jan 2, 2025 | VKTX Viking Therapeutics, Inc. | Award Stock Option (Right to Buy) | 18,800 | - | - | Direct |
| Oct 25, 2024 | VKTX Viking Therapeutics, Inc. | Exercise | 11,000 | $4.88 | $53,680 | Direct |
| Oct 25, 2024 | VKTX Viking Therapeutics, Inc. | Sale | 11,000 | $80.89 | $889,790 | Direct |
1-5 of 5 transactions